71.70
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $71.70, with a volume of 7.44M.
It is up +1.37% in the last 24 hours and up +6.46% over the past month.
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$70.73
Open:
$71.02
24h Volume:
7.44M
Relative Volume:
0.80
Market Cap:
$243.07B
Revenue:
$43.59B
Net Income/Loss:
$15.04B
P/E Ratio:
21.23
EPS:
3.3766
Net Cash Flow:
$10.74B
1W Performance:
+11.49%
1M Performance:
+6.46%
6M Performance:
-18.49%
1Y Performance:
-43.92%
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NVO
Novo Nordisk Adr
|
71.70 | 314.28B | 43.59B | 15.04B | 10.74B | 3.3766 |
![]()
LLY
Lilly Eli Co
|
812.69 | 723.06B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
168.30 | 407.97B | 90.63B | 22.66B | 16.40B | 9.35 |
![]()
ABBV
Abbvie Inc
|
190.28 | 337.08B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
117.70 | 227.39B | 55.19B | 13.65B | 16.81B | 6.86 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mar-13-25 | Upgrade | Kepler | Hold → Buy |
Mar-03-25 | Downgrade | Stifel | Buy → Hold |
Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
May-30-24 | Initiated | Goldman | Buy |
Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
Jan-23-24 | Initiated | Morgan Stanley | Overweight |
Jan-16-24 | Resumed | UBS | Neutral |
Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-02-23 | Initiated | Argus | Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-28-22 | Downgrade | UBS | Neutral → Sell |
Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
Jan-25-22 | Downgrade | Liberum | Hold → Sell |
Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Sep-29-20 | Initiated | Berenberg | Hold |
Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
May-11-20 | Downgrade | UBS | Buy → Neutral |
May-04-20 | Initiated | Cowen | Market Perform |
Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
Dec-11-18 | Resumed | Jefferies | Hold |
Oct-09-18 | Initiated | Guggenheim | Buy |
Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
HIMS STOCK UPDATE: Hims & Hers Health, Inc. (NYSE:HIMS) is being Sued for Securities Fraud – Contact BFA Law by August 25 Class Action Deadline - GlobeNewswire Inc.
Hims & Hers Health, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
European ADRs Inch Higher As Drugmakers Shine - Finimize
Novo Nordisk’s GLP-1 Reign Faces New Pressures In 2025 - Finimize
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
NVO’s 2025 Market Dance: Down -51.70% – Time to Invest? - investchronicle.com
Novo Nordisk's Cardiometabolic Foundation Supports Wide Moat - Morningstar
Novo Nordisk: Navigating Challenges to Dominate Diabetes and Obesity Therapies - AInvest
The Skinny On Novo Nordisk: This Slimmed-Down Stock May Be Worth A... Shot - Finimize
NVO’s Stock Woes: Down -31.04% in 6 Months, Down -31.04% in Just 5 Days - investchronicle.com
European Stocks Shine As ADRs Climb Higher - Finimize
After ousting CEO, Novo Nordisk reclaims crown as largest European company - MSN
Why Novo Nordisk Stock Just Popped - Barchart.com
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European ADRs Show Resilience In US Market - Finimize
Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat - Morningstar
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize
What Did We Find About Insider Trading At Novo Nordisk ADR (NYSE: NVO)? - Stocksregister
European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up - MSN
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):